Amgen, Inc. Plans For Biosimilar Launches

March 10, 2015 7:48 PM

4 0

Amgen, Inc. (NASDAQ:AMGN) is already on its way to ensure that it buoys some of the lost sales for its biotech drugs by venturing into the field of “copying others.” The company’s progress when it comes to its trials on biosimilar drugs is now going to be closely watched, now that the regulatory decision surrounding the production of Amgen’s cancer drug Neupogen has marked a change in stance when it comes to launching biosimilars.

Amgen appears to be relying on a 2010 US law, for what appears to be one of the most aspiring pipelines in the sector when it comes to replicating competitors' biologic treatment drugs. Amgen has plans to introduce five such products into the market by 2019.

Read more

To category page